Arstat Pharmaceuticals Inc

Arstat Pharmaceuticals is advancing transformational products that focus on significant unmet needs in women's health. Protected by 12 granted U.S. patents and a European (EPO) patent, the pipeline includes four drug candidates with proven efficacy and safety. Two products are Phase (confirmed by the FDA), and two other products are ready for Phase IIb. An addressable U.S. market is approximately 50 million women, with projected peak U.S. gross sales exceeding $3.4 billion. This is arguably one of the very best pharmaceutical portfolios in women's health. Arstat's most valuable asset is Nuvocept – the first and only oral contraceptive designed explicitly for women with overweight and obesity The FDA has already endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the US contraceptive market and address a high public health priority in the post-Roe world. The Company's Founder, President, and Chief Scientific Officer, Arkady Rubin, Ph.D, with 30+ years of industry experience (J&J, Pfizer). Dr. Rubin is a co-inventor of Ortho Tri-Cyclen Lo, the top-selling oral contraceptive in the U.S.($1.8B/year in current market conditions.) In addition, we are engaged in proprietary R&D activities. We developed and patented two transformational women's health products: NUVOCEPT - the first and only oral contraceptive designed for women with overweight and obesity (20 million US contraceptive users). Protected by 7 US patents and a European (EPO) patent. PREMRING - first-in-class vaginal ring for uterine fibroids and endometriosis (a much-needed solution for >15 million US women). Protected by 2 US Protected by 2 US patents. ENHANTA - first-in-class single non-hormonal therapy for painful and heavy menstrual periods (25 million US women). Protected by 3 US patents. Please visit the company's website for further details.